Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) shares traded down 9.6% on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $10.00 to $7.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Recursion Pharmaceuticals traded as low as $2.89 and last traded at $2.8750. Approximately 12,297,236 shares were traded during mid-day trading, a decline of 37% from the average session volume of 19,608,584 shares. The stock had previously closed at $3.18.
Several other research firms have also commented on RXRX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Thursday, October 15th. Morgan Stanley set a $5.90 target price on Recursion Pharmaceuticals in a research note on Friday, October 16th. Wall Street Zen raised Recursion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Monday, October 19th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $7.58.
Read Our Latest Analysis on Recursion Pharmaceuticals
Insiders Place Their Bets
In other news, CEO Najat Khan sold 22,408 shares of the company’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $3.52, for a total transaction of $78,876.16. Following the transaction, the chief executive officer owned 2,072,890 shares of the company’s stock, valued at $7,296,572.80. This represents a 1.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Robert Hershberg sold 25,000 shares of the stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $5.00, for a total value of $125,000.00. Following the transaction, the director owned 162,156 shares of the company’s stock, valued at $810,780. The trade was a 13.36% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 167,408 shares of company stock valued at $701,276 over the last ninety days. 6.65% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Recursion Pharmaceuticals
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. MCF Advisors LLC bought a new stake in shares of Recursion Pharmaceuticals in the second quarter valued at approximately $27,000. Jacobi Capital Management LLC bought a new position in Recursion Pharmaceuticals in the 3rd quarter worth approximately $31,000. Park Avenue Securities LLC bought a new position in Recursion Pharmaceuticals in the 3rd quarter worth approximately $47,000. Fund Advisors of America Inc FL purchased a new position in Recursion Pharmaceuticals in the 2nd quarter valued at approximately $45,000. Finally, Kestra Private Wealth Services LLC purchased a new position in Recursion Pharmaceuticals in the 3rd quarter valued at approximately $58,000. Institutional investors own 89.06% of the company’s stock.
Recursion Pharmaceuticals Trading Down 8.6%
The business’s fifty day simple moving average is $3.78 and its 200-day simple moving average is $3.49. The firm has a market cap of $1.81 billion, a P/E ratio of -3.23 and a beta of 1.15.
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last posted its earnings results on Monday, November 2nd. The company reported ($0.22) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.22). The firm had revenue of $18.55 million for the quarter, compared to the consensus estimate of $14.81 million. Recursion Pharmaceuticals had a negative return on equity of 47.85% and a negative net margin of 697.15%. During the same quarter in the prior year, the business posted ($0.36) earnings per share. As a group, research analysts expect that Recursion Pharmaceuticals, Inc. will post -0.89 earnings per share for the current fiscal year.
Recursion Pharmaceuticals Company Profile
Recursion Pharmaceuticals, Inc. is a biotechnology company that uses automation, large-scale biological and chemical data, and machine learning to discover and develop medicines. Its platform, known as Recursion OS, is designed to identify relationships between biological processes and potential treatments. The company develops drug candidates for areas including rare diseases and oncology, and it also works with pharmaceutical partners on drug discovery and development. Its research combines laboratory experiments with computational analysis to evaluate potential therapeutic targets and compounds.
Read More
- Five stocks we like better than Recursion Pharmaceuticals
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
